Viking Therapeutics, Inc.(VKTX) Stock Research - Grey Stern Research

Viking Therapeutics, Inc. (VKTX) Stock Analysis

$32.65 (0.28%)

VKTX Financial Performance


Use the table below to view Viking Therapeutics, Inc.'s financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q3 - 2024

Metric Value Ranking among Peers
Price $32.65 -
52 Week Low $20.75 -
52 Week High $99.41 -
Market Cap $3.6 Billion 6/20
Gross Margin 0% 10/20
Profit Margin 0% 6/20
EBITDA margin -100% 7/20
Q3 - 2024 Revenue $0 10/20
Q3 - 2024 Earnings -$24.9 Million 16/20
Q3 - 2024 Free Cash Flow -$22.0 Million 12/20
Trailing 4 Quarters Revenue $0 11/20
Trailing 4 Quarters Earnings -$99.2 Million 17/20
Quarterly Earnings Growth -11% 15/20
Annual Earnings Growth -24% 14/20
Quarterly Revenue Growth 0% 6/20
Annual Revenue Growth 0% 6/20
Cash On Hand $50.3 Million 12/20
Short Term Debt $480,000 11/20
Long Term Debt $755,000 15/20

Viking Therapeutics, Inc. Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Viking Therapeutics, Inc.'s metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE -1.00 4/20
PS -1.00 11/20
PB 3.99 8/20
PC 72.27 2/20
Liabilities to Equity 0.03 17/20
ROA -0.11 5/20
ROE -0.11 8/20
Current Ratio 35.47 1/20
Quick Ratio 35.19 1/20
Long Term Debt to Equity 0.00 12/20
Debt to Equity 0.00 11/20
Burn Rate 2.01 9/20
Cash to Cap 0.01 18/20
CCR 0.88 4/20
EV to EBITDA -1.00 5/20
EV to Revenue -1.00 11/20

Company Details

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

CEO: Dr. Brian Lian

Website: https://www.vikingtherapeutics.com

Address: 12340 El Camino Real Ste 250 San Diego, CALIFORNIA

Exchange: NASDAQ Capital Market

Industry: Biotechnology

Viking Therapeutics, Inc. Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Viking Therapeutics, Inc.. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
ImmunoGen, Inc. IMGN $8.7 Billion
Reata Pharmaceuticals, Inc. RETA $6.6 Billion
Sarepta Therapeutics, Inc. SRPT $11.3 Billion
Intercept Pharmaceuticals, Inc. ICPT $794.7 Million
Madrigal Pharmaceuticals, Inc. MDGL $6.4 Billion
PTC Therapeutics, Inc. PTCT $3.4 Billion
Axsome Therapeutics, Inc. AXSM $4.5 Billion
Seres Therapeutics, Inc. MCRB $131.0 Million
CohBar, Inc. CWBR $1.2 Million
AVROBIO, Inc. AVRO $5.2 Million
Hepion Pharmaceuticals, Inc. HEPA $3.3 Million
X4 Pharmaceuticals, Inc. XFOR $86.6 Million
Inozyme Pharma, Inc. INZY $87.4 Million
Elevation Oncology, Inc. ELEV $42.1 Million
Ocean Biomedical, Inc. OCEA $18.8 Million
Terns Pharmaceuticals, Inc. TERN $376.3 Million
Day One Biopharmaceuticals, Inc. DAWN $1.3 Billion
Enveric Biosciences, Inc. ENVB $3.7 Million
Acumen Pharmaceuticals, Inc. ABOS $99.1 Million
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
VKTX Income Statements
Quarter Year Revenue Earnings
Q3 2024 $ 0 -$24.9 Million
Q2 2024 $ 0 -$22.3 Million
Q1 2024 $ 0 -$27.4 Million
Q4 2023 $ 0 -$24.6 Million
Q3 2023 $ 0 -$22.5 Million
Q2 2023 $ 0 -$19.2 Million
Q1 2023 $ 0 -$18.5 Million
Q4 2022 $ 0 -$18.8 Million

View All

VKTX Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q3 2024 $50.3 Million $937.9 Million $1.2 Million $911.4 Million
Q2 2024 $43.9 Million $946.8 Million $1.1 Million $921.0 Million
Q1 2024 $195.6 Million $967.5 Million $1.2 Million $933.9 Million
Q4 2023 $55.5 Million $368.5 Million $1.3 Million $348.4 Million
Q3 2023 $37.2 Million $382.7 Million $1.3 Million $368.2 Million
Q2 2023 $69.5 Million $400.7 Million $1.4 Million $386.1 Million
Q1 2023 $18.4 Million $150.9 Million $1.5 Million $134.1 Million
Q4 2022 $36.6 Million $168.5 Million $1.6 Million $145.3 Million

View All

VKTX Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q3 2024 -$22.0 Million $0 $6.4 Million
Q2 2024 -$28.5 Million $0 -$151.7 Million
Q1 2024 -$6.1 Million $0 $140.1 Million
Q4 2023 -$17.6 Million $0 $18.3 Million
Q3 2023 -$19.7 Million $0 -$32.3 Million
Q2 2023 -$11.4 Million $0 $51.2 Million
Q1 2023 -$24.6 Million $0 -$18.3 Million
Q4 2022 -$10.9 Million $0 $7.2 Million

View All

Cookies

We use cookies to offer a better browsing experience. Cookies enhance site navigation, analyze site usage, and assist in our marketing efforts. By clicking Accept. you agree to the storing of cookies on your device. To refuse all non-required cookies, click on Decline.

Accept View Terms & Conditions